Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KAND 567

Next Previous
Search
Drug Profile

KAND 567

Alternative Names: AZD-8797; KAN-0440567; KAND-567

Latest Information Update: 29 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Kancera
  • Class 2 ring heterocyclic compounds; Amines; Analgesics; Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Neuroprotectants; Organic sulfur compounds; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Myocardial infarction; Ovarian cancer; Peritoneal cancer; SARS-CoV-2 acute respiratory disease
  • No development reported Autoimmune disorders; Breast cancer; Cancer pain; Cardiovascular disorders; Spinal cord injuries
  • Discontinued Multiple myeloma

Most Recent Events

  • 30 Aug 2024 Efficacy and adverse event data from a phase IIa FRACTAL trial in Myocardial infarction presented at the Annual Congress of the European Society of Cardiology 2024 (ESC-Card-2024)
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Spinal-cord-injuries in Sweden
  • 17 Jul 2024 Kancera completes the phase Ib portion of KANDOVA trial in Fallopian tube cancer in Sweden, Norway and Denmark (EudraCT2022-002792-11) (NCT06087289)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top